- citati u SCIndeksu: 0
- citati u CrossRef-u:0
- citati u Google Scholaru:[
 ]
- posete u poslednjih 30 dana:1
- preuzimanja u poslednjih 30 dana:1
|
|
|
2011, vol. 65, br. 1-2, str. 71-81
|
|
Predviđanje resorpcije i farmakokinetičkog profila karbamazepina iz tableta sa kontrolisanim oslobađanjem kod ljudi korišćenjem modela kunića
Predicting absorption and pharmacokinetic profile of carbamazepine from controlled-release tablet formulation in humans using rabbit model
aGalenika a.d., Institut za istraživanje i razvoj, Beograd
bUniverzitet u Beogradu, Farmaceutski fakultet, Institut za farmakokinetiku, Srbija
Sažetak
Farmaceutske formulacije sa kontrolisanim oslobađanjem imaju nekoliko prednosti u odnosu na konvencionalne dozirane oblike sa trenutnim oslobađanjem iste lekovite supstance. To se pre svega ogleda u redukovanoj učestalosti doziranja, smanjenoj pojavi i/ili intenzitetu neželjenih efekata, većoj farmakološkoj selektivnosti, redukovanoj fluktuaciji lekovite supstance u plazmi i boljoj podnošljivosti. Kada se posle završene registracije preparat nađe na tržištu, može se javiti potreba za manjim izmenama u formulaciji. U isto vreme on treba da ostane efikasan i bezbedan za pacijente, što može biti potvrđeno na osnovu koncentracije lekovite supstance u plazmi i farmakokinetičkih podataka. Poseban izazov predstavlja predviđanje resorpcije i farmakokinetičkih osobina lekovite supstance kod ljudi na osnovu određivanja in vitro brzine rastvaranja i farmakokinetičkih podataka dobijenih ispitivanjem na životinjskom modelu. Zbog toga je cilj ovog ispitivanja bio da se uspostavi korelacija farmakokinetičkih parametara između modela kunića i humanog modela za formulacije tableta sa kontrolisanim oslobađanjem karbamazepina (KBZ) kao i in vitro in vivo korelacija zasnovana na predviđenoj frakciji resorbovanog leka. I pored uočenih razlika u srednjim profilima plazma koncentracija, rezultati koji se odnose na predviđenu frakciju resorbovane lekovite supstance bili su gotovo identični. Na osnovu toga se može zaključiti da se kunić može koristiti kao reprezentativan in vivo model za predviđanje farmakokinetičkih karakteristika formulacije sa kontrolisanim oslobađanjem KBZ kod ljudi.
Abstract
Controlled-release (CR) pharmaceutical formulations offer several advantages over the conventional, immediate release dosage forms of the same drug, including reduced dosing frequency, decreased incidence and/or intensity of adverse effects, greater selectivity of pharmacological activity, reduced drug plasma fluctuation, and better compliance. After a drug product has been registered, and is already on market, minor changes in formulation might be needed. At the same time, the product has to remain effective and safe for patients that could be confirmed via plasma drug concentrations and pharmacokinetic characteristics. It is challenging to predict human absorption and pharmacokinetic characteristics of a drug based on the in vitro dissolution test and the animal pharmacokinetic data. Therefore, the objective of this study was to establish correlation of the pharmacokinetic parameters of carbamazepine (CBZ) CR tablet formulation between the rabbit and the human model, and to establish in vitro in vivo correlation (IVIVC) based on the predicted fractions of absorbed CBZ. Although differences in mean plasma concentration profiles were notified, the data concerning the predicted fraction of drug absorbed were almost superimposable. Accordingly, it can be concluded that rabbits may be representative as an in vivo model for predicting the pharmacokinetics of the CR formulation of CBZ in humans.
|
|
|
|
Reference
|
|
|
*** (1995) Note for guidance on validation of analytical procedures: Text and methodology (CPMP/ICH/381/95). London, UK, 1-15
|
|
|
*** (2003) Guideline on dossier requirements for type IA and type IB notifications. Bruxelles: European Comission
|
|
|
*** (1999) Guidance for industry: Validation of analytical procedures, methodology. CDER/FDA
|
|
   
|
Bialer, M., Arcavi, L., Sussan, S., Volosov, A., Yacobi, A., Moros, D., Levitt, B., Laor, A. (1998) Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy research, 32(3): 371-8
|
|
|
Cao, X., Gibbs, S.T., Fang, L., Miller, H.A., Landowski, C.P., Shin, H., Lennernas, H., Zhong, Y., Amidon, G.L., Yu, L.X., Sun, D. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharmaceutical research, 23(8): 1675-86
|
|
|
Homsek, I., Parojcic, J., Mitic, M., Simic, S., Cvetkovic, N., Đuric, Z. (2008) Development of a drug release methodology for carbamazepine CR tablets based on bioequivalence evaluation. Journal of Drug Delivery Science and Technology, vol. 18, br. 2, str. 139-144
|
|
|
Malinowski, H.J., Marroum, P.J. (1999) FDA requirements for controlled release products. u: Encyclopedia of controlled drug delivery, New York: John Wiley and Sons, vol. I, 381-94
|
|
|
Martindale (2009) The Extra Pharmacopoeia. London: The Pharmaceutical Press
|
|
|
McNamara, J.O. (1996) Drugs Effective in the Therapy of the Epilepsies. u: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. [ur.] Goodman & Gilman's pharmacological basis of therapeutics, New York, itd: McGraw-Hill, 9th ed., 473-5
|
|
|
Riad, L.E., Sawchuk, R.J. (1991) Absorptive clearance of carbamazepine and selected metabolites. Rabbit Intestine Pharm Res, 8, str. 1050-5
|
|
|
Rukhadze, M.D., Alexishvili, M.M., Okujava, N.V., Sebiskveradze, M.V., Okujava, V.M., Tsagareli, S.K. (2000) Interaction of carbamazepine and phenobarbital in rabbits. Biomedical chromatography, 14(5): 344-8
|
|
|
Simić, S., Ristić, S., Popadić, D., Homšek, I. (2010) The selective and sensitive HPLC method for determination of carbamazepine and carbamazepine epoxide in rabbit plasma. u: Word meeting on pharamceutics, biopharmaceutics and pharamaceutical tehnology (VII), Valeta, mart, 8-11
|
|
|
Stevens, R.E., Limsakun, T., Evans, G., Mason, D.H. (1998) Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). Journal of pharmaceutical sciences, 87(12): 1531-4
|
|
|
The Tegretol OROS osmotic release delivery system study group (1995) Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Neurology, 45, str. 1703-7
|
|
1
|
US Department of Health and Humane Service (1996) Guide for the care and use of laboratory animals. Bethesda, MD: NIH Publications, 85, 23
|
|
|
Veng-Pedersen, P., Gobburu, J.V., Meyer, M.C., Straughn, A.B. (2000) Carbamazepine level-A in vivo-in vitro correlation (IVIVC): A scaled convolution based predictive approach. Biopharmaceutics & drug disposition, 21(1): 1-6
|
|
|
Wilding, I.R., Davis, S.S., Hardy, J.G., Robertson, C.S., John, V.A., Powell, M.L., Leal, M., Lloyd, P., Walker, S.M. (1991) Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of N-labeled drug to healthy volunteers. Br J Clin Pharm, 32, str. 573-9
|
|
|
|
|